Drug Database · Clinicians

Glimepiride + Metformin + Pioglitazone

Brands (2) Tri-Senza, Tripride-2Show all

Oral blood glucose lowering drug combination; Oral hypoglycemic agent PH FDA category
Fixed-dose combination.

Rx · Prescription drug2 PH productsVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

  • Use: Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ] . US FDA label

    Kidney dosing: Glimepiride (single-agent)
    Show full dosing details
    CrCl ≥60 mL/min
    Start 1 or 2 mg once daily with breakfast; increase by 1 to 2 mg every 1 to 2 weeks; maximum 8 mg/day (label). Older adults: start 1 mg.
    CrCl 30–59 mL/min
    Start 1 mg once daily and titrate slowly (label 2.1, 8.6): hypoglycemia risk is higher in kidney impairment, and the M1 and M2 metabolites accumulate (M1 AUC 2.3-fold and M2 AUC 8.6-fold higher at CrCl <20). Studied at CrCl 10–60 mL/min with doses of 1 to 8 mg.
    CrCl 15–29 mL/min
    Start 1 mg once daily and titrate slowly (label 2.1, 8.6): hypoglycemia risk is higher in kidney impairment, and the M1 and M2 metabolites accumulate (M1 AUC 2.3-fold and M2 AUC 8.6-fold higher at CrCl <20). Studied at CrCl 10–60 mL/min with doses of 1 to 8 mg.
    CrCl <15 mL/min (not on dialysis)
    Start 1 mg once daily and titrate slowly (label 2.1, 8.6): hypoglycemia risk is higher in kidney impairment, and the M1 and M2 metabolites accumulate (M1 AUC 2.3-fold and M2 AUC 8.6-fold higher at CrCl <20). Studied at CrCl 10–60 mL/min with doses of 1 to 8 mg. No separate advice for CrCl <15; hypoglycemia can be prolonged. Specialist judgment.
    Hemodialysis (intermittent)
    Not studied in dialysis; the label gives no dialysis dose. Removal by hemodialysis unlikely (over 99.5% protein-bound). Specialist input; prefer agents with lower hypoglycemia risk.
    Peritoneal dialysis
    Not studied; no dose in label. Specialist input. Metabolites accumulate in kidney impairment; risk of prolonged hypoglycemia (label 8.6, 12.3).
    CRRT
    No data. Specialist input; insulin usually preferred in acute illness.
    • Dialyzable? Not stated; unlikely (protein binding over 99.5%; label).
    • Monitoring Blood glucose (hypoglycemia, which can be prolonged), hemoglobin A1c, kidney function. Hold in acute illness with poor intake.

    From the Glimepiride monograph (renalcarematters.com, reviewed).

  • Use: Metformin Hydrochloride Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. US FDA label

    Kidney dosing: Metformin (single-agent)
    Show full dosing details
    eGFR ≥60
    Usual dosing. Assess kidney function before starting and periodically (label).
    eGFR 30–59
    eGFR 45–59: usual dose; consider dose reduction if at high risk of lactic acidosis. eGFR 30–44: label advises not to start; if continuing, reduce to a maximum of 1,000 mg/day (KDIGO 2022; ADA-KDIGO 2022). Recheck eGFR every 3 to 6 months.
    eGFR 15–29
    Contraindicated (label). Stop if eGFR falls below 30.
    eGFR <15 (not on dialysis)
    Contraindicated (label).
    Hemodialysis (intermittent)
    Contraindicated (eGFR <30 per label).
    Peritoneal dialysis
    Contraindicated (eGFR <30 per label).
    CRRT
    Not appropriate; contraindicated in severe kidney impairment (label).
    • Dialyzable? Yes: dialyzable with clearance up to 170 mL/min under good hemodynamic conditions; hemodialysis may help remove drug in suspected overdose (label).
    • Monitoring eGFR before starting and at least periodically; more often in older adults. Stop before or at the time of iodinated contrast in at-risk patients per label. Hold temporarily during acute illness with dehydration, sepsis, hypoxia or acute heart failure, during procedures with restricted food or fluid intake, and for acute kidney injury; restart when eating and kidney function is stable (label 5.1).

    From the Metformin monograph (renalcarematters.com, reviewed).

  • Use: Monotherapy and Combination Therapy ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14) ] . US FDA label

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Film-coated tablet: 500 mg/15 mg/1 mg
  • Tablet: 500 mg/15 mg/2 mg

Registered products in the Philippines

2 products registered with the Food and Drug Administration (FDA) Philippines list Glimepiride + Metformin + Pioglitazone as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Glimepiride + Metformin + Pioglitazone
Package insert
Tri-SenzaMetformin hydrochloride + Pioglitazone (as hydrochloride) + Glimepiride
500 mg/15 mg/1 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.
DR-XY42996
Nov 21, 2028
Tripride-2Metformin Hydrochloride + Pioglitazone ( as Hydrochloride) + Glimepiride
500 mg/15 mg/2 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 10's, 30's and 100's)
RxVAT-exempt
Micro Labs LimitedIndia
Brown & burk Philippines Inc.Importer: Brown & Burk Philippines inc.
DRP-12941
Oct 2, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .